MGN 1703 by MOLOGEN,AG of Germany has rec'd positive

pete43lost_at_sea said:

you are a tease steve
can you give us something more to go than that, if you get anything else.

if its out of germany, well it must be good.

they make those sexy fast cars, so the cancer drugs must be good.

progession free survival, that means we live longer right ? why do they have to make simple concepts complex.

i know, so the doctors can charge alot to explain it to us.

hugs,
pete

Can't find much
It seems that an area of interest is immunotherapy that targets TLR (toll like receptors) which are found on tumours - the idea is that agonists to these receptrs(drugs that bind to these receptors) increase antigen presentation (stuff being presented by the tumour that the body recognises as foreign) and so trigger stonger immune responses against the tumours. The aim is to undermine the ways tumours hide from teh immune system.

There is a 55 person phase 2 trail of MGN1703 in Germany inpatients with colorectal cancer with 'positive results'- I can't access anything more specific without paying for papers. Doesn't seem to have made the media much but is mentioned in Nature which is usually pretty reliable.

Anyone else access more?

steve

coloCan said:

I rec'd this off a site called "www.4-trader" and not much else
was mentioned on this....At one point I was writing down drugs going into trial but i no longer do that; my first hearing of MGN 1703 was in Nov 2010. Sorry i have no further info on this so i'll toss out this test for KRAS at:
fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310899.htm

and a little technical stuff on:"Explaining the Unexplainable:EGFR Antibodies in CRC," at:
http://jco.ascopubs.org/content/30/15/1735.full

"Nature", Steve, is,as you stated, quite reliable and if you or others want to get blinded by science, try reading this:

nature.com/nature/journal/vaop/ncurrent/full/nature11282.html

"Recurrent R-spondin fusions in colon cancer"...........

If anyone comphrehends, kindly interpret for me......... steve

``

Info - MGN1703
National Cancer Institute

Clinical Trials . gov

American Society of Clinical Oncology (ASCO)

Info - MGN1703

coloCan said:

I rec'd this off a site called "www.4-trader" and not much else
was mentioned on this....At one point I was writing down drugs going into trial but i no longer do that; my first hearing of MGN 1703 was in Nov 2010. Sorry i have no further info on this so i'll toss out this test for KRAS at:
fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310899.htm

and a little technical stuff on:"Explaining the Unexplainable:EGFR Antibodies in CRC," at:
http://jco.ascopubs.org/content/30/15/1735.full

"Nature", Steve, is,as you stated, quite reliable and if you or others want to get blinded by science, try reading this:

nature.com/nature/journal/vaop/ncurrent/full/nature11282.html

"Recurrent R-spondin fusions in colon cancer"...........

If anyone comphrehends, kindly interpret for me......... steve

``

Heavy reading
Blimey- had to get my biochem book out to make sense of that one. IT is very preclinical at present but they are looking at the pathway of communication between receptors onthe outside of cells and the nucleus in the centre of cells which is done through wnt signalling ( a pathway of proteins that communicates stuff rom outside the cell to the nucleus where all the DNA sits). R-spondins stimulate this pathway and mutations in these are probably related to cancerous cell proliferation. They therefore think these may be new targets for treatments.

They haven't taken it any further to develop these new treatments but it is a totally new avenue that will be explored. I sense it is at the stage where developments will help our kids (considering all the increased risk of cancer we have passed to them) rather than us- these things take a long time to get from this to treatment stage and most don't make it.

Interesting read though- anything else you find I'm always happy to look at. Accessing recent Nature articles on line is quite tricky as they are mainly controlled.

steve

coloCan said:

Just read of something called Reolysin,
http://pharmabiz.com/NewsDetails.aspx?aid=70669&sid=2

starting Phase I for Kras mutation crc.....

Interesting
It is a virus that doesn't grow in normal cells but in cancer cells with KRAS mutations it grows to the point of destroying the cell. It is in Phase 3 for some other cancers and Phase 2 in colorectal should happen pretty soon which will use it in combination with FOLFIRI and avastin.

Again a new approach to fighting cancer that opens up new hopes for those for whom the current drugs don't work.

steve